<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02228889</url>
  </required_header>
  <id_info>
    <org_study_id>2014H0041</org_study_id>
    <nct_id>NCT02228889</nct_id>
  </id_info>
  <brief_title>Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey E Janis, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the clinical outcomes of two commonly used,
      FDA-approved biologic meshes in hernia repair and abdominal wall reconstruction (Strattice
      and XenMatrix). The two meshes are derived from pig skin from which cells have been removed
      and which have been sterilized. The two meshes are made by two different companies using
      different processes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized-controlled trial comparing two porcine acellular matrices
      in abdominal wall reconstruction. It is single-blind (patients are blinded to the type of
      mesh used while surgeons are not).

      Our goals in this study are:

        1. PRIMARY OUTCOME: To compare the overall complication rates between two non-cross-linked
           porcine dermal matrices (XenMatrix and Strattice) at 30 days and 1 year postoperatively

        2. SECONDARY OUTCOMES

      i. To compare the rate of Surgical Site Occurrences (SSOs) between XenMatrix and Strattice in
      abdominal wall reconstruction at 30 days and 1 year postoperatively

        1. Infection

        2. Seroma

        3. Hematoma

        4. Wound dehiscence

        5. Skin necrosis

        6. Formation of enterocutaneous fistula

        7. Mesh infection ii. To compare the hernia recurrence rate between XenMatrix and Strattice
           at 30 days and 1 year postoperatively iii. To compare the bulge rate between XenMatrix
           and Strattice at 30 days and 1 year postoperatively iv. To compare to changes in patient
           pain, physical functioning and quality of life after hernia repair between XenMatrix and
           Strattice, preoperatively, and at 1 year postoperatively A. Pain assessment: Patient
           Reported Outcomes Measurement Information System (PROMIS) Pain Intensity survey, PROMIS
           Pain Interference survey B. Physical functioning assessment: PROMIS Physical Function C.
           Quality of life assessment: Hernia-Related Quality-of-Life (HerQLes) survey
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall complication rate at 1 year</measure>
    <time_frame>1 year postoperatively</time_frame>
    <description>Compare the overall complication rates between two non-cross-linked porcine dermal matrices (XenMatrix and Strattice) at 1 year postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Surgical Site Occurrences (SSOs) at 1 year</measure>
    <time_frame>1 year postoperatively</time_frame>
    <description>Compare the rate of Surgical Site Occurrences (SSOs) between XenMatrix and Strattice in abdominal wall reconstruction at 1 year postoperatively. These include:
Infection
Seroma
Hematoma
Wound dehiscence
Skin necrosis
Formation of enterocutaneous fistula
Mesh infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hernia recurrence rate at 30 days</measure>
    <time_frame>30 days postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bulge rate at 30 days</measure>
    <time_frame>30 days postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall complication rate at 30 days</measure>
    <time_frame>30 days postoperatively</time_frame>
    <description>Compare the overall complication rates between two non-cross-linked porcine dermal matrices (XenMatrix and Strattice) at 30 days postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Surgical Site Occurrences (SSOs) at 30 days</measure>
    <time_frame>30 days postoperatively</time_frame>
    <description>Compare the rate of Surgical Site Occurrences (SSOs) between XenMatrix and Strattice in abdominal wall reconstruction at 30 days postoperatively. These include:
Infection
Seroma
Hematoma
Wound dehiscence
Skin necrosis
Formation of enterocutaneous fistula
Mesh infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hernia recurrence rate at 1 year</measure>
    <time_frame>1 year postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bulge rate at 1 year</measure>
    <time_frame>1 year postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity preoperatively</measure>
    <time_frame>At the last office visit before surgery (average of 1-3 weeks before surgery)</time_frame>
    <description>Measure patient pain intensity of the two groups (XenMatrix and Strattice), at the last office visit before surgery (average of 1-3 weeks before surgery), using the PROMIS Pain Intensity survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain interference preoperatively</measure>
    <time_frame>At the last office visit before surgery (average of 1-3 weeks before surgery)</time_frame>
    <description>Measure patient pain interference of the two groups (XenMatrix and Strattice), at the last office visit before surgery (average of 1-3 weeks before surgery), using the PROMIS Pain Interference survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity postoperatively</measure>
    <time_frame>1 year postoperatively</time_frame>
    <description>Measure patient pain intensity of the two groups (XenMatrix and Strattice), at 1 year postoperatively, using the PROMIS Pain Intensity survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain interference postoperatively</measure>
    <time_frame>1 year postoperatively</time_frame>
    <description>Measure patient pain interference of the two groups (XenMatrix and Strattice), at 1 year postoperatively, using the PROMIS Pain Interference survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical functioning preoperatively</measure>
    <time_frame>At the last office visit before surgery (average of 1-3 weeks before surgery)</time_frame>
    <description>Measure physical functioning of the two groups (XenMatrix and Strattice), at the last office visit before surgery (average of 1-3 weeks before surgery), using the PROMIS Physical Function survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical functioning postoperatively</measure>
    <time_frame>1 year postoperatively</time_frame>
    <description>Measure physical functioning of the two groups (XenMatrix and Strattice), at 1 year postoperatively, using the PROMIS Physical Function survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life preoperatively</measure>
    <time_frame>At the last office visit before surgery (average of 1-3 weeks before surgery)</time_frame>
    <description>Measure patient quality of life of the two groups (XenMatrix and Strattice), at the last office visit before surgery (average of 1-3 weeks before surgery), using the HerQLes survey (Hernia Related Quality of Life survey)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life postoperatively</measure>
    <time_frame>1 year postoperatively</time_frame>
    <description>Measure patient quality of life of the two groups (XenMatrix and Strattice), at 1 year postoperatively, using the HerQLes survey (Hernia Related Quality of Life survey)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hernia, Ventral</condition>
  <condition>Intestinal Fistula</condition>
  <condition>Fibromatosis, Abdominal</condition>
  <arm_group>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abdominal wall reconstruction with Strattice Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XenMatrix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abdominal wall reconstruction with XenMatrix Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Abdominal wall reconstruction with Strattice</intervention_name>
    <description>Abdominal wall reconstruction using Strattice</description>
    <arm_group_label>Strattice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess pain intensity at last office visit preoperatively</intervention_name>
    <description>Assess patient pain intensity preoperatively using the PROMIS Pain Intensity survey (average of 1-3 weeks preoperatively)</description>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess pain interference at last office visit preoperatively</intervention_name>
    <description>Assess pain interference preoperatively using the PROMIS pain interference survey (average of 1-3 weeks preoperatively)</description>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess physical functioning at last office visit preoperatively</intervention_name>
    <description>Assess physical functioning preoperatively using the PROMIS physical functioning survey (average of 1-3 weeks preoperatively)</description>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess patient quality of life at last office visit preoperatively</intervention_name>
    <description>Assess patient quality of life preoperatively, using the HerQLes survey (average of 1-3 weeks preoperatively)</description>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess patient pain intensity postoperatively</intervention_name>
    <description>Assess patient pain intensity at 1 year postoperatively using the PROMIS Pain Intensity survey</description>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess pain interference postoperatively</intervention_name>
    <description>Assess pain interference at 1 year postoperatively using the PROMIS Pain Interference survey</description>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess physical functioning postoperatively</intervention_name>
    <description>Assess physical functioning at 1 year postoperatively using the PROMIS Physical Functioning Survey</description>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess quality of life postoperatively</intervention_name>
    <description>Assess quality of life at 1 year postoperatively using the HerQLes survey</description>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess hernia recurrence at 30 days postoperatively</intervention_name>
    <description>Assess hernia recurrence at 30 days</description>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess bulge at 30 days postoperatively</intervention_name>
    <description>Assess bulge at 30 days</description>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess Surgical Site Occurrences at 30 days postoperatively</intervention_name>
    <description>Assess Surgical Site Occurrences at 30 days</description>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess hernia recurrence at 1 year postoperatively</intervention_name>
    <description>Assess hernia recurrence at 1 year postoperatively</description>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess bulge at 1 year postoperatively</intervention_name>
    <description>Assess bulge at 1 year postoperatively</description>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess Surgical Site Occurrences at 1 year postoperatively</intervention_name>
    <description>Assess Surgical Site Occurrences at 1 year postoperatively</description>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess overall complications at 30 days postoperatively</intervention_name>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess overall complications at 1 year postoperatively</intervention_name>
    <arm_group_label>Strattice</arm_group_label>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Abdominal wall reconstruction with XenMatrix</intervention_name>
    <description>Abdominal wall reconstruction with XenMatrix</description>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Strattice</intervention_name>
    <description>Strattice mesh</description>
    <arm_group_label>Strattice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XenMatrix</intervention_name>
    <description>Xenmatrix mesh</description>
    <arm_group_label>XenMatrix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18

          -  Patients presenting for elective hernia repair, with Ventral Hernia Working Group
             (VHWG) grade 2 or above (Patients with a hernia who need hernia repair due to hernia
             size, discomfort, risk of bowel incarceration, effect on physical function), and who
             have comorbidities or contamination making the use of synthetic mesh contraindicated)

          -  Patients deemed to be good surgical candidates, with no active life-threatening
             cardiac disease, pulmonary disease, renal disease, hematologic disease (patients who
             can have a major surgical procedure without an exceedingly high risk of medical
             complications such as pulmonary edema, myocardial infarction, pulmonary embolism,
             renal failure, life-threatening bleeding, stroke).

          -  Patients presenting for resection of large abdominal wall tumors who are expected to
             undergo have tumor extirpative defect that would require biologic mesh for closure
             (patients with a large tumor of the abdominal wall who will have a large defect in
             their fascia after resection, who need biologic mesh for reinforcement).

        Exclusion Criteria:

          -  Known allergy to porcine products

          -  Active smokers (within the past 4 weeks) presenting for elective hernia repair

          -  Patients with active life-threatening cardiac disease, pulmonary disease, renal
             disease, hematologic disease presenting for elective hernia repair

          -  Patients presenting for emergent hernia repair (in the setting of bowel strangulation,
             necrosis, penetrating trauma) as it will be difficult to consent those patients for
             the study preoperatively

          -  Patients with severe systemic sepsis

          -  Patients with frank purulence in the wound
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey E Janis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ibrahim Z Khansa, MD</last_name>
    <phone>614-293-9030</phone>
    <email>ibrahim.khansa@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeffrey E Janis, MD</last_name>
    <phone>614-366-1704</phone>
    <email>jeffrey.janis@osumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey E Janis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ibrahim Z Khansa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel S Eiferman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Steinberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vimal Narula, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2014</study_first_submitted>
  <study_first_submitted_qc>August 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2014</study_first_posted>
  <last_update_submitted>April 8, 2018</last_update_submitted>
  <last_update_submitted_qc>April 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Jeffrey E Janis, MD</investigator_full_name>
    <investigator_title>Professor of Plastic Surgery, Vice-Chairman</investigator_title>
  </responsible_party>
  <keyword>Hernia</keyword>
  <keyword>Abdominal wall reconstruction</keyword>
  <keyword>Abdominal wall defect</keyword>
  <keyword>Porcine mesh</keyword>
  <keyword>Component separation</keyword>
  <keyword>Abdominal wall tumor</keyword>
  <keyword>Desmoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Fibroma</mesh_term>
    <mesh_term>Hernia, Ventral</mesh_term>
    <mesh_term>Intestinal Fistula</mesh_term>
    <mesh_term>Fibromatosis, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

